In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly & Co.

www.lilly.com

Latest From Eli Lilly & Co.

Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Financing StartUps and SMEs

Lilly Expands Migraine Franchise With Reyvow Approval

Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the preventive agent approved in 2018.

Approvals Business Strategies

Pharma Will Embrace Basket And Umbrella Trials, Despite Challenges

New approaches in study design and methodology, including master protocol trials, are being adopted by biopharma.
Clinical Trials FDA
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register